SecBot SecBot
Biotech Drug Report Generated Nov 8, 2026

CDX-622

CLDX·Celldex Therapeutics, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1/1b
Time to market
At least 4-6 years away, assuming successful completion of Phase 1b, Phase 2, and Phase 3 trials plus regulatory review. The drug is still in very early clinical development.
Why 2/10
No hard dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for CDX-622 in the next 12 months. The next event would be Phase 1b proof-of-mechanism data in asthma, but no date has been disclosed. CDX-622 is an early-stage pipeline asset that represents a small fraction of Celldex's value; the company's primary value driver is barzolvolimab (Phase 3 for CSU).
Actionable Insight NEUTRAL

CDX-622 has no scheduled binary catalyst in the next 12 months. The next meaningful event would be Phase 1b proof-of-mechanism data in asthma, but no date has been disclosed. For Celldex, the far larger catalyst is the barzolvolimab BLA submission planned for 2027 and any Phase 2 atopic dermatitis data expected in late 2026. CDX-622 is pipeline optionality, not a near-term value driver.

Price Chart

Loading chart...

Executive Summary

CDX-622 is an early-stage (Phase 1/1b) bispecific antibody targeting SCF and TSLP, developed by Celldex Therapeutics (CLDX). Positive Phase 1 data presented at EAACI in June 2026 showed rapid, dose-dependent reductions in serum tryptase (mast cell depletion) with a clean safety profile. The drug is advancing into Phase 1b proof-of-concept studies in asthma, allergic rhinitis, and food allergy. However, CDX-622 is a pipeline extension asset for Celldex, whose primary value driver is barzolvolimab (CDX-0159), a Phase 3 anti-KIT antibody for chronic spontaneous urticaria with positive Phase 3 data and a BLA submission planned for 2027. CDX-622 has no hard dated catalyst in the next 12 months, making it a small part of the Celldex thesis.

How It Works

CDX-622 is a bispecific antibody that simultaneously targets two immune-signaling proteins: SCF (stem cell factor) and TSLP (thymic stromal lymphopoietin). By neutralizing SCF, it blocks KIT signaling selectively in mast cells, depleting these allergy-driving immune cells. By also blocking TSLP, it may further dampen allergic inflammation. This dual mechanism is designed to treat mast cell-driven allergic diseases such as asthma, allergic rhinitis, and food allergies.

Trial Status

Phase 1 first-in-human study completed with positive results presented at EAACI June 2026. A Phase 1b proof-of-mechanism study in mild-to-moderate asthma is ongoing. Additional proof-of-concept studies in allergic rhinitis and food allergy are planned.

The Two-Sided Case

▲ Bull Case4
Positive Phase 1 data showed rapid, dose-dependent reductions in serum tryptase (indicating tissue mast cell depletion) with no dose-limiting toxicities or serious adverse events, validating a novel mechanism.
The bispecific approach targeting both SCF and TSLP could differentiate CDX-622 from other mast cell-targeting therapies and from barzolvolimab, expanding Celldex's platform into additional allergic indications.
Celldex has a strong balance sheet ($650.3M cash as of Q3 2026) with runway through 2028, providing ample funding to advance CDX-622 through early-stage development without near-term financing risk.
Institutional accumulation was strong in Q2 2026 (BlackRock added 30%, T. Rowe Price doubled, Baker Bros added 78%, Driehaus initiated a new position), signaling confidence in Celldex's broader pipeline.
▼ Bear Case5
CDX-622 is in very early clinical development (Phase 1/1b) with no efficacy data in patients yet; the Phase 1 data only showed biomarker changes (tryptase reduction), not clinical outcomes.
No hard dated catalyst exists for CDX-622 in the next 12 months, making it a low-impact near-term driver for CLDX stock.
Celldex's primary value driver is barzolvolimab; CDX-622 is a small pipeline extension asset that will not materially move the stock until later-stage data emerges.
The company faces competition from other mast cell-targeting therapies, including its own barzolvolimab and external candidates from larger players.
Celldex is pre-revenue with widening losses ($75.6M net loss in Q3 2026) and recently filed a shelf registration (S-3ASR), creating potential overhang for future dilution.

Upcoming Catalysts

  • Phase 1b proof-of-mechanism data in mild-to-moderate asthma (date not disclosed)
  • Initiation of proof-of-concept studies in allergic rhinitis and food allergy (timing not disclosed)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Celldex Therapeutics, Inc. 8-K CLDX ·Originating report

Sources · 5

Hover a chip for the title
1 globenewswire.com2 sec.gov3 sec.gov4 globenewswire.com5 markets.businessinsider.com